Advertising in the medicinal cannabis sector in Australia is unlike any other area of healthcare marketing. Clinics and brands face a unique challenge: navigating the overlapping requirements of both the Therapeutic Goods Administration (TGA) and AHPRA/National Boards. With prescription-only status and some of the strictest advertising restrictions in the world, even seemingly small details—like wording on a website, use of imagery, or patient testimonials—can be deemed unlawful promotion.

This article unpacks the key rules from both regulators, clarifies what clinics and brands can and cannot say, and highlights safer strategies to build awareness without risking compliance.

Registered nurses with appropriate training and experience will be able to prescribe Schedule 2, 3, 4, and 8 medicines under a collaborative prescribing model. In this blog post, we explore how this systemic change brings both opportunity and responsibility.